Literature DB >> 16960555

Tumor-derived fibronectin is involved in melanoma cell invasion and regulated by V600E B-Raf signaling pathway.

Cédric Gaggioli1, Guillaume Robert, Corine Bertolotto, Olivier Bailet, Patricia Abbe, Anne Spadafora, Philippe Bahadoran, Jean-Paul Ortonne, Véronique Baron, Robert Ballotti, Sophie Tartare-Deckert.   

Abstract

Melanomas are malignant tumors of melanocytes that, if not detected early, are highly aggressive and poorly treatable. Activation of extracellular signal-regulated (ERK)/mitogen-activated protein (MAP) kinase signaling is commonly found in melanomas mainly through oncogenic mutations of B-Raf. We previously reported that activation of ERK/MAP kinase stimulates synthesis of fibronectin by upregulating the transcription factor early growth response-1 (Egr-1). To further analyze the link between ERK/MAP kinase pathway and fibronectin in melanoma, we have studied the regulation and role of fibronectin produced by melanoma cells bearing oncogenic B-Raf mutation. We show that fibronectin is expressed in situ during tumor progression and that high fibronectin and Egr-1 levels are found in cells expressing this mutation. Expression of active mutants of B-Raf induces fibronectin, whereas endogenous fibronectin is inhibited by small interfering RNA (siRNA)-mediated depletion of B-Raf or Egr-1. In contrast, stimulation of ERK pathway is insufficient to promote fibronectin upregulation in normal melanocytes. Finally, we show that suppression of fibronectin by siRNA leads to decreased melanoma cell invasiveness in vitro. These results reveal a tumor-specific regulation of fibronectin by constitutive ERK/MAP kinase signaling and indicate that self-production of fibronectin may play a role in melanoma tumorigenesis, by promoting tumor cell invasion.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16960555     DOI: 10.1038/sj.jid.5700524

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  22 in total

1.  Induction of heparanase-1 expression by mutant B-Raf kinase: role of GA binding protein in heparanase-1 promoter activation.

Authors:  Geetha Rao; Dingxie Liu; Mingzhao Xing; Jordi Tauler; Richard A Prinz; Xiulong Xu
Journal:  Neoplasia       Date:  2010-11       Impact factor: 5.715

2.  Deconstructing the role of the ECM microenvironment on drug efficacy targeting MAPK signaling in a pre-clinical platform for cutaneous melanoma.

Authors:  Benjamin H Blehm; Nancy Jiang; Yorihisa Kotobuki; Kandice Tanner
Journal:  Biomaterials       Date:  2015-04-17       Impact factor: 12.479

3.  Melanoma prognostic model using tissue microarrays and genetic algorithms.

Authors:  Bonnie E Gould Rothberg; Aaron J Berger; Annette M Molinaro; Antonio Subtil; Michael O Krauthammer; Robert L Camp; William R Bradley; Stephan Ariyan; Harriet M Kluger; David L Rimm
Journal:  J Clin Oncol       Date:  2009-11-02       Impact factor: 44.544

Review 4.  BRAF(V600E) and microenvironment in thyroid cancer: a functional link to drive cancer progression.

Authors:  Carmelo Nucera; Jack Lawler; Sareh Parangi
Journal:  Cancer Res       Date:  2011-03-29       Impact factor: 12.701

5.  Spleen tyrosine kinase functions as a tumor suppressor in melanoma cells by inducing senescence-like growth arrest.

Authors:  Olivier Bailet; Nina Fenouille; Patricia Abbe; Guillaume Robert; Stéphane Rocchi; Nadège Gonthier; Christophe Denoyelle; Michel Ticchioni; Jean-Paul Ortonne; Robert Ballotti; Marcel Deckert; Sophie Tartare-Deckert
Journal:  Cancer Res       Date:  2009-03-17       Impact factor: 12.701

6.  alpha5beta1-integrin expression is essential for tumor progression in experimental lung cancer.

Authors:  Jesse Roman; Jeffrey D Ritzenthaler; Sussane Roser-Page; XiaoJuan Sun; ShouWei Han
Journal:  Am J Respir Cell Mol Biol       Date:  2010-01-15       Impact factor: 6.914

Review 7.  Overcoming resistance to BRAF inhibitors.

Authors:  Imanol Arozarena; Claudia Wellbrock
Journal:  Ann Transl Med       Date:  2017-10

8.  Mcl-1 is required for melanoma cell resistance to anoikis.

Authors:  Karen Boisvert-Adamo; Whitney Longmate; Ethan V Abel; Andrew E Aplin
Journal:  Mol Cancer Res       Date:  2009-04       Impact factor: 5.852

Review 9.  Is EGR1 a potential target for prostate cancer therapy?

Authors:  Delphine Gitenay; Véronique T Baron
Journal:  Future Oncol       Date:  2009-09       Impact factor: 3.404

Review 10.  The Thyroid Tumor Microenvironment: Potential Targets for Therapeutic Intervention and Prognostication.

Authors:  Laura MacDonald; Jonathan Jenkins; Grace Purvis; Joshua Lee; Aime T Franco
Journal:  Horm Cancer       Date:  2020-06-17       Impact factor: 3.869

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.